Outsourced R&D With a small team and notable funding but minimal revenue, Chroma Therapeutics appears positioned to outsource R&D. This signals strong sales opportunities for CRO/CMO services, early-stage discovery partnerships, and potential licensing of discovery assets.

Strategic Alliances The funding profile and early-stage revenue imply a focus on de-risking programs through collaborations. Targeted opportunities include co-development deals, asset licensing, or research partnerships with pharma and biotech players seeking to accelerate pipelines without large internal headcounts.

UK Market Located in the United Kingdom, Chroma Therapeutics may benefit from European biotech networks and regional funding programs. This creates avenues for regulatory consulting, grant collaborations, and access to EU clinical trial support through local partners.

Digital Presence The tech stack shows legacy web technologies alongside Google Analytics, suggesting room for modernization of the website and marketing analytics. This presents a sales angle to offer modern web development, digital marketing, content strategy, and analytics services to improve investor and partner outreach.

Partnership Ready The company positions itself in a landscape with major players like Genentech and Astex, indicating an opportunity to pursue nimble, early-stage collaborations with big pharma or mid-sized biotechs through flexible discovery and licensing models.